Epidemiology of systemic sclerosis

被引:76
作者
Nikpour, Mandana [1 ,2 ]
Stevens, Wendy M. [1 ,2 ]
Herrick, Ariane L. [3 ]
Proudman, Susanna M. [4 ]
机构
[1] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic 3065, Australia
[2] St Vincents Hosp, Dept Rheumatol, Fitzroy, Vic 3065, Australia
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Epidemiol Unit, Manchester M13 9PT, Lancs, England
[4] Royal Adelaide Hosp, Dept Rheumatol, Adelaide, SA 5000, Australia
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2010年 / 24卷 / 06期
关键词
systemic sclerosis; epidemiology; risk factor; prognosis; SCLERODERMA RENAL CRISIS; PULMONARY ARTERIAL-HYPERTENSION; INTERSTITIAL LUNG-DISEASE; LONG-TERM OUTCOMES; QUALITY-OF-LIFE; IMPROVED SURVIVAL; FIBRILLIN-1; GENE; SOUTH-AUSTRALIA; RISK-FACTOR; ASSOCIATION;
D O I
10.1016/j.berh.2010.10.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis (SSc) is a multisystem auto-immune disease. The two main subtypes of SSc (limited and diffuse) typically have differing courses and prognoses. New classification criteria have been proposed to identify SSc in the earliest stages, before skin involvement. Over the past three decades, there has been an apparent increase in the incidence of SSc to approximately 20 per million, possibly due to improved diagnosis. The most extensively studied environmental associations of SSc are organic solvents and silica but no single risk factor has emerged. Recent genetic studies have identified new susceptibility factors including human leucocyte antigen (HLA) haplotypes and polymorphisms in immune regulatory genes. Despite earlier disease recognition and effective treatment for some of its complications, SSc still carries a high mortality, particularly due to cardiorespiratory complications. Although some predictors of organ involvement and outcomes have been identified, novel biomarkers are greatly needed. Due to low disease prevalence, large multicentre research collaborations are required. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:857 / 869
页数:13
相关论文
共 50 条
[41]   Association of osteopontin regulatory polymorphisms with systemic sclerosis [J].
Barizzone, Nadia ;
Marchini, Maurizio ;
Cappiello, Francesca ;
Chiocchetti, Annalisa ;
Orilieri, Elisabetta ;
Ferrante, Daniela ;
Corrado, Lucia ;
Mellone, Simona ;
Scorza, Raffaella ;
Dianzani, Umberto ;
D'Alfonso, Sandra .
HUMAN IMMUNOLOGY, 2011, 72 (10) :930-934
[42]   Pathogenesis of interstitial lung disease in systemic sclerosis [J].
Goldman, Nina ;
Ong, Voon H. ;
Denton, Christopher P. .
RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2024, 5 (03) :141-151
[43]   Systemic sclerosis is a risk factor of incident psoriasis: results from a nationwide cohort study [J].
Kwon, Oh Chan ;
Han, Kyungdo ;
Park, Min-Chan .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[44]   Genetics of systemic sclerosis [J].
Bossini-Castillo, Lara ;
Lopez-Isac, Elena ;
Mayes, Maureen D. ;
Martin, Javier .
SEMINARS IN IMMUNOPATHOLOGY, 2015, 37 (05) :443-451
[45]   Treatment of systemic sclerosis [J].
Thoreau, Benjamin ;
Chaigne, Benjamin ;
Renaud, Arthur ;
Mouthon, Luc .
PRESSE MEDICALE, 2021, 50 (01)
[46]   Genetics of systemic sclerosis [J].
Ishikawa, Yuki ;
Terao, Chikashi .
JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2020, 5 (03) :192-201
[47]   Biomarkers in systemic sclerosis [J].
Castro, Susan V. ;
Jimenez, Sergio A. .
BIOMARKERS IN MEDICINE, 2010, 4 (01) :133-147
[48]   Systemic pharmacotherapy approaches for the treatment of systemic sclerosis [J].
Di Donato, Stefano ;
Mcmahan, Zsuzsanna H. ;
Hughes, Michael .
EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (05) :551-566
[49]   Systemic sclerosis refractory disease: From the skin to the heart [J].
Almeida, Isabel ;
Faria, Raquel ;
Vita, Pedro ;
Vasconcelos, Carlos .
AUTOIMMUNITY REVIEWS, 2011, 10 (11) :693-701
[50]   An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis [J].
McMahan, Zsuzsanna H. ;
Volkmann, Elizabeth R. .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (16) :2041-2056